Dimensional Fund Advisors LP Acquires 102,297 Shares of Xencor, Inc. (NASDAQ:XNCR)

Dimensional Fund Advisors LP raised its stake in Xencor, Inc. (NASDAQ:XNCR - Free Report) by 7.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,501,532 shares of the biopharmaceutical company's stock after acquiring an additional 102,297 shares during the quarter. Dimensional Fund Advisors LP owned approximately 2.15% of Xencor worth $34,509,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in XNCR. Vanguard Group Inc. boosted its stake in shares of Xencor by 5.5% during the fourth quarter. Vanguard Group Inc. now owns 8,017,366 shares of the biopharmaceutical company's stock valued at $184,239,000 after purchasing an additional 418,040 shares in the last quarter. Geode Capital Management LLC boosted its position in Xencor by 12.3% during the 4th quarter. Geode Capital Management LLC now owns 1,634,876 shares of the biopharmaceutical company's stock worth $37,578,000 after buying an additional 179,526 shares during the period. Loomis Sayles & Co. L P grew its holdings in Xencor by 21.3% during the 4th quarter. Loomis Sayles & Co. L P now owns 1,092,346 shares of the biopharmaceutical company's stock worth $25,102,000 after acquiring an additional 192,080 shares during the last quarter. Finepoint Capital LP acquired a new position in Xencor in the 4th quarter valued at approximately $15,167,000. Finally, Charles Schwab Investment Management Inc. increased its position in Xencor by 0.6% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 630,640 shares of the biopharmaceutical company's stock valued at $14,492,000 after acquiring an additional 3,652 shares during the period.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on XNCR shares. StockNews.com lowered Xencor from a "hold" rating to a "sell" rating in a research report on Friday, March 14th. Wells Fargo & Company reduced their target price on Xencor from $37.00 to $33.00 and set an "overweight" rating on the stock in a report on Friday, February 28th. Wedbush restated an "outperform" rating and set a $31.00 price target on shares of Xencor in a report on Wednesday, April 30th. Finally, William Blair started coverage on shares of Xencor in a research report on Monday, April 21st. They set an "outperform" rating for the company. One analyst has rated the stock with a sell rating, seven have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, Xencor currently has a consensus rating of "Moderate Buy" and an average price target of $32.86.

Insider Activity at Xencor

In other news, EVP Nancy Valente sold 4,616 shares of the business's stock in a transaction on Friday, May 2nd. The shares were sold at an average price of $11.03, for a total transaction of $50,914.48. Following the sale, the executive vice president now owns 49,169 shares in the company, valued at approximately $542,334.07. The trade was a 8.58 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. 5.23% of the stock is owned by corporate insiders.

Xencor Trading Down 5.6 %

Xencor stock traded down $0.47 during mid-day trading on Wednesday, hitting $7.99. The company's stock had a trading volume of 1,982,935 shares, compared to its average volume of 636,181. The stock has a market cap of $568.50 million, a price-to-earnings ratio of -2.50 and a beta of 0.99. The business has a 50 day moving average price of $11.11 and a 200-day moving average price of $17.90. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.23 and a quick ratio of 6.23. Xencor, Inc. has a 12 month low of $7.16 and a 12 month high of $27.24.

Xencor (NASDAQ:XNCR - Get Free Report) last posted its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.06). Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. Xencor's revenue was up 104.6% on a year-over-year basis. During the same period in the previous year, the firm earned ($1.11) EPS. As a group, analysts forecast that Xencor, Inc. will post -3.68 EPS for the current year.

Xencor Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.